NAD+ Injections and IV Therapy: Hype vs. Evidence for Anti-Aging
- NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme for cellular energy production and DNA repair. It declines with age.
- Intravenous NAD+ therapy is aggressively marketed by wellness clinics at $500–1,500 per session for anti-aging, addiction recovery, and “brain restoration.”
- Evidence for IV NAD+ is extremely limited , a handful of small, uncontrolled studies and abundant anecdotes. No large-scale randomized trials exist.
- Oral precursors (NMN, NR) have far better safety and bioavailability data and achieve the same biochemical goal at a fraction of the cost.
- The NAD+ decline hypothesis is scientifically legitimate. The IV delivery method is not.
What Is NAD+ and Why Does It Matter?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It plays a central role in metabolism, serving as a critical electron carrier in the mitochondrial electron transport chain , the process that converts food into cellular energy (ATP).
Beyond energy production, NAD+ is a substrate for several important enzyme families:
- Sirtuins: Proteins that regulate cellular health, stress resistance, and aging , they require NAD+ to function
- PARPs: DNA repair enzymes that consume NAD+ when fixing damaged DNA
- CD38: An enzyme that degrades NAD+ and increases with age
NAD+ levels decline by approximately 50% between ages 40 and 60. This decline is one of the most consistent biochemical markers of aging and has been implicated in mitochondrial dysfunction, metabolic decline, and reduced cellular repair capacity. Restoring NAD+ levels is a scientifically legitimate anti-aging strategy.
The IV NAD+ Industry
Wellness clinics across the United States now offer intravenous NAD+ therapy, typically marketed with claims like:
- “Reverse biological aging”
- “Restore brain function and mental clarity”
- “Detoxify and repair cells”
- “Boost energy and metabolism”
- “Overcome addiction and withdrawal symptoms”
Sessions typically last 2-4 hours and cost $500–1,500 each, with “protocols” of 5-10 sessions recommended. A full course can easily exceed $10,000.
These clinics are not required to prove efficacy. IV therapy falls into a regulatory grey zone , the FDA regulates the drugs but has limited authority over how licensed physicians use them off-label. This creates an environment where expensive treatments can be marketed aggressively with minimal evidence.
The Evidence Gap
The evidence for IV NAD+ therapy is remarkably thin:
For anti-aging: No randomized controlled trials exist. The biological plausibility of NAD+ restoration is strong, but this plausibility does not validate the intravenous route. Oral NAD+ precursors achieve the same biochemical endpoint.
For addiction recovery: A few small, uncontrolled pilot studies have been conducted, primarily by clinics that offer the treatment. A 2019 review identified only case reports and one small open-label study. No blinded, placebo-controlled trials have demonstrated efficacy for substance use disorders.
For brain function: No clinical trial data. Claims about “mental clarity” and “brain restoration” are based on anecdotes and biological speculation.
For athletic performance: No convincing evidence. A small 2021 study of 8 participants found no performance benefit from oral NAD+ precursors, let alone IV administration.
The contrast between the marketing claims and the evidence base is stark. IV NAD+ therapy is a case study in how a legitimate biological target (NAD+ decline with aging) can be exploited to sell an expensive, invasive, and unproven intervention.
Why Oral Precursors Are Superior
The irony of the IV NAD+ trend is that oral NAD+ precursors (nicotinamide mononucleotide . NMN, and nicotinamide riboside . NR) have substantially more research support, better safety data, lower cost, and no need for intravenous access.
NMN and NR are orally bioavailable precursors that cells convert to NAD+ through established enzymatic pathways. Multiple human trials have demonstrated:
- Oral NR increases blood NAD+ levels by 40-90% within weeks
- NMN is well tolerated at doses up to 1,200 mg/day in human studies
- Safety data from multiple randomized trials show no serious adverse effects
The biochemical endpoint , increased cellular NAD+ , is achieved by both oral precursors and IV administration. The oral route is cheaper ($1-3/day vs. $500-1,500/session), more convenient, far better studied, and doesn’t require sitting in a clinic with an IV for hours.
If NAD+ restoration is the goal, oral NMN or NR is the evidence based approach. IV NAD+ is an expensive delivery mechanism for a goal that can be achieved orally.
Why IV NAD+ Is Unpleasant (and Potentially Hazardous)
Beyond the lack of efficacy evidence, IV NAD+ administration is notoriously uncomfortable. Patients routinely report:
- Intense chest pressure and shortness of breath during infusion
- Severe nausea and abdominal cramping
- Headache and lightheadedness
- A sensation described as “impending doom”
These side effects are so predictable that clinics typically slow the infusion rate significantly, extending session duration to 4+ hours. The mechanism is not well understood, but may involve NAD+’s role in activating TRPM2 ion channels on immune cells.
Any medical intervention should meet a basic standard: the benefits must outweigh the harms. For IV NAD+ therapy, the benefits are unproven and the harms , while typically transient , are well documented and unpleasant. This is an unfavorable risk-benefit ratio for an elective anti-aging treatment.
Additionally, any intravenous access carries risks of infection, phlebitis (vein inflammation), infiltration (fluid leaking into surrounding tissue), and air embolism. These risks are low in professional settings but are non-zero and unnecessary when oral alternatives exist.
The Legitimate Science vs. The Exploitation
The NAD+ decline hypothesis is real science. David Sinclair’s lab at Harvard, Shin-ichiro Imai’s work at Washington University, and numerous other research groups have produced high quality evidence that NAD+ repletion may be a viable anti-aging strategy. This is why Nous Vita has an evidence based NMN supplement guide.
The problem is not the science. The problem is the gap between what the science shows (NAD+ precursors may support healthy aging) and what the clinics sell (IV NAD+ will reverse aging, cure addiction, and restore your brain). This gap is filled with marketing, not evidence.
Conclusion
If you are interested in NAD+ restoration as an anti-aging strategy:
- Start with the evidence: oral NMN or NR have human trial data supporting safety and NAD+ elevation
- Skip the IV: there is no evidence that intravenous administration produces benefits beyond what oral precursors achieve
- Save your money: $500-1,500 per IV session vs. $1-3 per day for oral precursors
The NAD+ IV therapy industry is selling an expensive, uncomfortable, and unproven delivery method for a legitimate biochemical goal. The goal is sound. The method is not.
References
[5] Time Magazine. “Why ‘Anti-Aging’ Peptide Shots Are Trending on Social Media.” 2025.